{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:15:59Z","timestamp":1740107759806,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002806","name":"Carl Zeiss Meditec AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002957","name":"Technische Universit\u00e4t Dresden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lasers Med Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>To report the safety and effectiveness of selective laser trabeculoplasty (SLT) using the SLT mode of the VISULAS<jats:sup>\u00ae<\/jats:sup> green laser in patients with primary open-angle glaucoma (POAG). Twelve months results are presented. Retrospective extension in 4 German centers of an initially prospective interventional multicenter 3-month clinical investigation using the VISULAS<jats:sup>\u00ae<\/jats:sup> green SLT (Carl Zeiss Meditec AG, Jena, Germany) in patients with POAG who either needed treatment escalation or commenced treatment and had an IOP\u2009\u2265\u200917mmHg at baseline, with no previous glaucoma or other ocular surgery. Non-overlapping laser spots (100) were applied in a single session to 360\u00b0 of the trabecular meshwork (TM). Glaucoma medications were not changed up to the 3-month visit. From 3 to 12\u00a0months, patients were managed according to routine standard of care. Outcome measures included IOP reduction, further glaucoma interventions, and adverse events from baseline to month 12. 25 eyes of 25 POAG patients (mean age 65.8\u2009\u00b1\u20098.5; modified intention to treat \u2013 mITT \u2013group) were included in the extension study. Six eyes (24%) underwent additional glaucoma treatment or changed glaucoma therapy; the remaining 19 eyes (76%) had stable glaucoma therapy (SGT group) with no further glaucoma intervention or change in glaucoma medications (mean number of preoperative glaucoma medications: 2.3\u2009\u00b1\u20091.34). In the SGT group, mean baseline IOP (mmHg) was reduced from 20.0\u2009\u00b1\u20092.11 at baseline to 17.4\u2009\u00b1\u20093.25 and 16.2\u2009\u00b1\u20091.83 at 6 to 12 months, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001): 52.6% had\u2009\u2265\u200920% IOP reduction at 12 months. Potential device- or procedure-related adverse events were mild to moderate and resolved without sequelae. SLT performed with the VISULAS<jats:sup>\u00ae<\/jats:sup> green laser reduced IOP in eyes with POAG up to 12 months with no relevant safety issues. The results are comparable to other reported SLT studies.<\/jats:p>","DOI":"10.1007\/s10103-024-04252-3","type":"journal-article","created":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T01:51:11Z","timestamp":1734227471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of VISULAS\u00ae green selective laser trabeculoplasty: 12\u00a0months retrospective data"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4400-6004","authenticated-orcid":false,"given":"Karin R.","family":"Pillunat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian T. A.","family":"Kretz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Koinzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz E.","family":"Pillunat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karsten","family":"Klabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,15]]},"reference":[{"key":"4252_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487\u2013497. https:\/\/doi.org\/10.1016\/S0002-9394(98)00223-2","journal-title":"Am J Ophthalmol"},{"key":"4252_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B et al (2002) Reduction of intraocular pressure and glaucoma progression: Results from the early manifest glaucoma trial. Arch Ophthalmol 120:1268\u20131279. https:\/\/doi.org\/10.1001\/archopht.120.10.1268","journal-title":"Arch Ophthalmol"},{"key":"4252_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Gordon MO (2002) The ocular hypertension treatment study. Arch Ophthalmol 120:701. https:\/\/doi.org\/10.1001\/archopht.120.6.701","journal-title":"Arch Ophthalmol"},{"key":"4252_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/ICU.0000000000000732","volume":"32","author":"M T\u00f6teberg-Harms","year":"2021","unstructured":"T\u00f6teberg-Harms M, Meier-Gibbons F (2021) Is laser trabeculoplasty the new star in glaucoma treatment? Curr Opin Ophthalmol 32:141\u2013147. https:\/\/doi.org\/10.1097\/ICU.0000000000000732","journal-title":"Curr Opin Ophthalmol"},{"key":"4252_CR5","doi-asserted-by":"publisher","unstructured":"Pillunat KR, Kretz FTA, Koinzer S et al (2023) Effectiveness and safety of VISULAS\u00ae green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation. Int Ophthalmol 43:2215\u20132224. https:\/\/doi.org\/10.1007\/s10792-022-02617-7","DOI":"10.1007\/s10792-022-02617-7"},{"key":"4252_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/IJG.0b013e31817d2386","volume":"17","author":"T Realini","year":"2008","unstructured":"Realini T (2008) Selective laser trabeculoplasty. J Glaucoma 17:497\u2013502. https:\/\/doi.org\/10.1097\/IJG.0b013e31817d2386","journal-title":"J Glaucoma"},{"key":"4252_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/eye.2017.273","volume":"32","author":"A Garg","year":"2018","unstructured":"Garg A, Gazzard G (2018) Selective laser trabeculoplasty: past, present, and future. Eye 32:863\u2013876. https:\/\/doi.org\/10.1038\/eye.2017.273","journal-title":"Eye"},{"key":"4252_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/lsm.20907","volume":"42","author":"JPM Wood","year":"2010","unstructured":"Wood JPM, Plunkett M, Previn V et al (2010) Rapid and delayed death of cultured trabecular meshwork cells after selective laser trabeculoplasty. Lasers Surg Med 42:326\u2013337. https:\/\/doi.org\/10.1002\/lsm.20907","journal-title":"Lasers Surg Med"},{"key":"4252_CR9","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/IJG.0b013e318218287f","volume":"21","author":"LJ Katz","year":"2012","unstructured":"Katz LJ, Steinmann WC, Kabir A et al (2012) Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma. J Glaucoma 21:460\u2013468. https:\/\/doi.org\/10.1097\/IJG.0b013e318218287f","journal-title":"J Glaucoma"},{"key":"4252_CR10","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","volume":"393","author":"G Gazzard","year":"2019","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D et al (2019) Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet 393:1505\u20131516. https:\/\/doi.org\/10.1016\/S0140-6736(18)32213-X","journal-title":"Lancet"},{"key":"4252_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ophtha.2022.09.009","volume":"130","author":"G Gazzard","year":"2023","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D et al (2023) Laser in glaucoma and ocular hypertension (LiGHT) trial. Ophthalmology 130:139\u2013151. https:\/\/doi.org\/10.1016\/j.ophtha.2022.09.009","journal-title":"Ophthalmology"},{"key":"4252_CR12","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/IJG.0b013e3181e3d2c1","volume":"20","author":"E Martow","year":"2011","unstructured":"Martow E, Hutnik CML, Mao A (2011) SLT and adjunctive medical therapy. J Glaucoma 20:266\u2013270. https:\/\/doi.org\/10.1097\/IJG.0b013e3181e3d2c1","journal-title":"J Glaucoma"},{"key":"4252_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/aos.13094","volume":"94","author":"KR Pillunat","year":"2016","unstructured":"Pillunat KR, Spoerl E, Elfes G, Pillunat LE (2016) Preoperative intraocular pressure as a predictor of selective laser trabeculoplasty efficacy. Acta Ophthalmol 94:692\u2013696. https:\/\/doi.org\/10.1111\/aos.13094","journal-title":"Acta Ophthalmol"},{"key":"4252_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/OPTH.S84996","volume":"10","author":"J Song","year":"2016","unstructured":"Song J (2016) Complications of selective laser trabeculoplasty: a review. Clin Ophthalmol 10:137. https:\/\/doi.org\/10.2147\/OPTH.S84996","journal-title":"Clin Ophthalmol"},{"key":"4252_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.survophthal.2014.06.006","volume":"60","author":"MOM Wong","year":"2015","unstructured":"Wong MOM, Lee JWY, Choy BNK et al (2015) Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Surv Ophthalmol 60:36\u201350. https:\/\/doi.org\/10.1016\/j.survophthal.2014.06.006","journal-title":"Surv Ophthalmol"},{"key":"4252_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1136\/bjophthalmol-2020-316178","volume":"105","author":"MOM Wong","year":"2021","unstructured":"Wong MOM, Lai IS, Chan PP et al (2021) Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. Br J Ophthalmol 105:514\u2013520. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316178","journal-title":"Br J Ophthalmol"},{"key":"4252_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/IJG.0000000000001534","volume":"29","author":"S Elahi","year":"2020","unstructured":"Elahi S, Rao HL, Dumitru A, Mansouri K (2020) Predictors of success in selective laser trabeculoplasty: Data from the lausanne laser trabeculoplasty registry. J Glaucoma 29:550\u2013555. https:\/\/doi.org\/10.1097\/IJG.0000000000001534","journal-title":"J Glaucoma"},{"key":"4252_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/opo.12611","volume":"39","author":"O Chadwick","year":"2019","unstructured":"Chadwick O, Chia SN, Rotchford A (2019) Establishing an allied health professional delivered selective laser trabeculoplasty service in Scotland. Ophthalmic Physiol Opt 39:216\u2013223. https:\/\/doi.org\/10.1111\/opo.12611","journal-title":"Ophthalmic Physiol Opt"},{"key":"4252_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12886-016-0299-9","volume":"16","author":"BA Francis","year":"2016","unstructured":"Francis BA, Loewen N, Hong B et al (2016) Repeatability of selective laser trabeculoplasty for open-angle glaucoma. BMC Ophthalmol 16:128. https:\/\/doi.org\/10.1186\/s12886-016-0299-9","journal-title":"BMC Ophthalmol"},{"key":"4252_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40662-016-0041-y","volume":"3","author":"M De Keyser","year":"2016","unstructured":"De Keyser M, De Belder M, De Belder S, De Groot V (2016) Where does selective laser trabeculoplasty stand now? A review. Eye Vision 3:10. https:\/\/doi.org\/10.1186\/s40662-016-0041-y","journal-title":"Eye Vision"},{"key":"4252_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.preteyeres.2016.12.004","volume":"57","author":"T Carreon","year":"2017","unstructured":"Carreon T, van der Merwe E, Fellman RL et al (2017) Aqueous outflow - A continuum from trabecular meshwork to episcleral veins. Prog Retin Eye Res 57:108\u2013133. https:\/\/doi.org\/10.1016\/j.preteyeres.2016.12.004","journal-title":"Prog Retin Eye Res"},{"key":"4252_CR22","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1136\/bjophthalmol-2019-315489","volume":"104","author":"P Alaghband","year":"2020","unstructured":"Alaghband P, Galvis EA, Daas A et al (2020) Predictors of selective laser trabeculoplasty success in open angle glaucoma or ocular hypertension: does baseline tonography have a predictive role? Br J Ophthalmol 104:1390\u20131393. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-315489","journal-title":"Br J Ophthalmol"},{"key":"4252_CR23","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0161-6420(98)91129-0","volume":"105","author":"MA Latina","year":"1998","unstructured":"Latina MA, Sibayan SA, Shin DH et al (1998) Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty). Ophthalmology 105:2082\u20132090. https:\/\/doi.org\/10.1016\/S0161-6420(98)91129-0","journal-title":"Ophthalmology"}],"container-title":["Lasers in Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10103-024-04252-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10103-024-04252-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10103-024-04252-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T15:41:18Z","timestamp":1738338078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10103-024-04252-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,15]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4252"],"URL":"https:\/\/doi.org\/10.1007\/s10103-024-04252-3","relation":{},"ISSN":["1435-604X"],"issn-type":[{"type":"electronic","value":"1435-604X"}],"subject":[],"published":{"date-parts":[[2024,12,15]]},"assertion":[{"value":"12 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and was approved by the responsible Ethics Commission at the TU Dresden (MPG ff-EK-24012020) and the involved local Ethics Commissions at the participating study sites as well as by the German Competent Authority BfArM (EUDAMED: CIV-19\u201312-031046). The study is registered at clinicaltrials.gov under NCT04519814. The extension was also approved by EC and BfArM.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"K. R. P. has received lecture fees from Allergan, Abbvie, Thea, Santen, and Novartis.F.T.A.K. has received compensation for consulting, lectures, travel costs, and grants from BVI, Carl Zeiss Meditec, Teleon, Hoya, VSY, Bausch & Lomb.S.K. has received compensation for consulting from Carl Zeiss Meditec AG.P.M. has no financial interests to disclose.L. E. P. has received lecture fees from Allergan and Santen and is on the Advisory.Board for Allergan, Santen, and Aerie, and received grant support from Novartis.K.K. has received lecture fees from Abbvie, Glaukos, iStar medical, Oertli, and Carl Zeiss Meditec, has received compensation for consulting from Carl Zeiss Meditec and is on the Advisory Board for Abbvie, iStar Medical, Oertli and Santen.None of the authors has any financial interest or any conflict of interest related to the\u00a0subject matter.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"293"}}